Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies
ACS Pharmacology & Translational Science · 12.07.2024 · 7 (7) · 2125-2142
DOI: 10.1021/acsptsci.4c00208 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 02.07.2024. Verfasst von Gabriele Carullo und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, Siena 53100, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: European Commission, Associazione Italiana per la Ricerca sul Cancro, Regione Toscana.
Abstract (Originalsprache)
Blood cancers encompass a group of diseases affecting the blood, bone marrow, or lymphatic system, representing the fourth most commonly diagnosed cancer worldwide. Leukemias are characterized by the dysregulated proliferation of myeloid and lymphoid cells with different rates of progression (acute or chronic). Among the chronic forms, hairy cell leukemia (HCL) is a rare disease, and no drugs have been approved to date. However, acute myeloid leukemia (AML) is one of the most aggressive malignancies, with a low survival rate, especially in cases with FLT3-ITD mutations. Epigenetic modifications have emerged as promising strategies for the treatment of blood cancers. Epigenetic modulators, such as histone deacetylase (HDAC) inhibitors, are increasingly used for targeted cancer therapy. New hydroxamic acid derivatives, preferentially inhibiting HDAC6 (5a-q), were developed and their efficacy was investigated in different blood cancers, including multiple myeloma (MM), HCL, and AML, pointing out their pro-apoptotic effect as the mechanism of cell death. Among the inhibitors described, 5c, 5g, and 5h were able to rescue the hematopoietic phenotype in vivo using the FLT3-ITD zebrafish model of AML. 5c (leuxinostat) proved its efficacy in cells from FLT3-ITD AML patients, promoting marked acetylation of α-tubulin compared to histone H3, thereby confirming HDAC6 as a preferential target for this new class of hydroxamic acid derivatives at the tested doses.
Autor:innen und Institutionen
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, Siena 53100, Italy.
- Department of Medicine, Surgery, Dentistry "Scuola Medica Salernitana", University of Salerno, Via S. Allende, Baronissi, SA 84081, Italy.
- Department of Medical Biotechnology and Translational Medicine, University of Milan, LITA, Fratelli Cervi 93, Segrate, MI 20054, Italy.
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via de Crecchio 7, Naples 80138, Italy.
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Borsari 46, Ferrara 44121, Italy.
- Department of Translational Medicine, University of Ferrara, Via Borsari 46, Ferrara 44121, Italy.
ORCID-Profile: Gabriele Carullo, Giovanna Panzeca, Sandra Gemma, Anna Ramunno, Francesca Galvani, Alessio Lodola, Marco Mor, Rosaria Benedetti, Stefania Butini, Lucia Altucci, Giuseppe Campiani
Förderung
- European Commission
- Associazione Italiana per la Ricerca sul Cancro
- Regione Toscana
- Ministero dell'Universit? e della Ricerca
Zitieren
APA
Carullo, G., Rossi, S., Giudice, V., Pezzotta, A., Chianese, U., Scala, P., Carbone, S., Fontana, A., Panzeca, G., Pasquini, S., Contri, C., Gemma, S., Ramunno, A., Saponara, S., Galvani, F., Lodola, A., Mor, M., Benedetti, R., Selleri, C., …, & Campiani, G. (2024). Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies. ACS Pharmacology & Translational Science, 7(7), 2125-2142. https://doi.org/10.1021/acsptsci.4c00208
Vancouver
Carullo G, Rossi S, Giudice V, Pezzotta A, Chianese U, Scala P, et al. Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies. ACS Pharmacology & Translational Science. 2024;7(7):2125-2142. doi:10.1021/acsptsci.4c00208
BibTeX
@article{Carullo2024,
author = {Carullo, Gabriele and Rossi, Sara and Giudice, Valentina and Pezzotta, Alex and Chianese, Ugo and Scala, Pasqualina and Carbone, Sabrina and Fontana, Anna and Panzeca, Giovanna and Pasquini, Silvia and Contri, Chiara and Gemma, Sandra and Ramunno, Anna and Saponara, Simona and Galvani, Francesca and Lodola, Alessio and Mor, Marco and Benedetti, Rosaria and Selleri, Carmine and Varani, Katia and Butini, Stefania and Altucci, Lucia and Vincenzi, Fabrizio and Pistocchi, Anna and Campiani, Giuseppe},
title = {Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies},
journal = {ACS Pharmacology & Translational Science},
year = {2024},
volume = {7},
number = {7},
pages = {2125--2142},
doi = {10.1021/acsptsci.4c00208}
}
EUVIMED